cargrilintide NEW

Product Information
Product Name: Cagrilintide 
CAS No.: 1415456-99-3
Purity: >99.0%
Molecular Formula: C187H291N45O59
Molecular Weight: 4409g/mol
Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18diacid-γ-Glu-OEG-OEG)]-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
Appearance: White Lyophilized powder
Reconstitution: Required 
Storage:After reconstitution store at 2°C - 8°C

Cagrilintide is under development for the treatment of obesity and type 2 diabetes. The drug candidate is administered as a once-daily and once-weekly subcutaneous formulation. It is a long-acting amylin analogue. Amylin is co-located with insu in secretory granules and co-secreted with insu by pancreatic beta cells in response to food intake. 
CagriSema is a combination medication of the GLP-1 receptor agonist semaglutide and cagrilintide. Cagrilinitide mimics the hormone amylin, which is produced by the pancreas. Together with insu, amylin makes people feel satiated or full after eating a meal.
CagriSema is a once-weekly injection of semaglutide and cagrilintide. Phase 2 clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising new type 2 diabetes treatment.